A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

Therapeutic responses of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR mutations. However, a proportion of NSCLCs carrying EGFR mutations still progress on EGFR-TKI underlining the imperfect corr...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Hui, Lei, Qian, Wang, Chengdi, Wang, Zhoufeng, Chen, Hai, Wang, Gang, Yang, Na, Huang, Dan, Yu, Quanwei, Yao, Mengling, Xiao, Xue, Zhu, Guonian, Cheng, Cheng, Li, Yangqian, Li, Feng, Tian, Panwen, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663578/
https://www.ncbi.nlm.nih.gov/pubmed/36376325
http://dx.doi.org/10.1038/s41467-022-34627-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663578/
https://www.ncbi.nlm.nih.gov/pubmed/36376325
http://dx.doi.org/10.1038/s41467-022-34627-5

Ejemplares similares